Summit Therapeu ADR (SMMT) Stock Price, Quote & News

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Industry: Biotechnology

Sector: Healthcare

Phone: 305 203 2034

Website: www.smmttx.com

Address:

601 Brickell Key Drive, Suite 1000, Miami, United States

TruthBroker2 Sep. 20 at 10:30 PM

$SMMT

0 · Reply

Doozio Sep. 20 at 2:40 PM

$SUPN thing about MNDY 🐑 lows and tight weekly closes. $SYM thing about Roger coming out of the tightness and $SMMT thing about potential tightness bahhhhtom of the base 🐒🍌🧠⏰♾️

1 · Reply

goooooolddust Sep. 20 at 4:31 AM

$SMMT they just keep buying lol

0 · Reply

Newyork_ Sep. 20 at 12:37 AM

$SMMT oh Thankgod Cramer is bearish on us . 😂😂😂 ima load more .

1 · Reply

Knowhentoprofit Sep. 19 at 9:15 PM

$SMMT hahaha

2 · Reply

TruthBroker2 Sep. 19 at 8:04 PM

$SMMT

0 · Reply

Magic8BallResponse Sep. 19 at 7:15 PM

$SMMT Feeling that tingle.....

0 · Reply

BigFishLittleBish Sep. 19 at 6:06 PM

$SMMT Look no further than a racist "investment" profile saying some deliberately false bullshit. What the fuck are you even talking about? Seriously? "China man readout" - In 3 words you literally just told us all we need to know about the validity and quality of your opinion. And it's worse than horseshit. Nothing was off in the patient section. Stop huffing ether buddy.

3 · Reply

TruthBroker2 Sep. 19 at 5:45 PM

$SMMT

0 · Reply

BigBeardTrader Sep. 19 at 5:11 PM

$SMMT https://www.marketbeat.com/instant-alerts/filing-rockland-trust-co-buys-shares-of-400000-summit-therapeutics-plc-smmt-2025-09-19/

0 · Reply

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Sep 16, 2025, 4:31 PM EDT - 4 days ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 10, 2025, 12:43 AM EDT - 10 days ago

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 9, 2025, 9:12 AM EDT - 11 days ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

CERO RENB

Sep 8, 2025, 3:36 PM EDT - 12 days ago

Summit Therapeutics (SMMT) WCLC Update Call (Transcript)

Sep 8, 2025, 8:28 AM EDT - 12 days ago

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

Sep 8, 2025, 8:10 AM EDT - 12 days ago

New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

NFE

Sep 7, 2025, 6:08 AM EDT - 13 days ago

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Sep 7, 2025, 3:30 AM EDT - 13 days ago

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Sep 3, 2025, 7:00 AM EDT - 17 days ago

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Aug 27, 2025, 2:43 PM EDT - 24 days ago

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Aug 14, 2025, 7:00 AM EDT - 5 weeks ago

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Aug 11, 2025, 5:03 PM EDT - 5 weeks ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Jul 14, 2025, 3:00 PM EDT - 2 months ago

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 4, 2025, 5:10 AM EDT - 2 months ago

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain

AZN

Jun 30, 2025, 8:00 AM EDT - 2 months ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD

Jun 6, 2025, 4:44 PM EDT - 3 months ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 5, 2025, 8:00 AM EDT - 3 months ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 2, 2025, 2:52 PM EDT - 3 months ago

Summit Therapeutics: Market Overreaction Creates Opportunity

Jun 2, 2025, 9:10 AM EDT - 3 months ago

Is SMMT Stock A Buy After Its Recent Plunge?

May 30, 2025, 2:50 PM EDT - 4 months ago

Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release

May 30, 2025, 9:27 AM EDT - 4 months ago

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

May 30, 2025, 9:01 AM EDT - 4 months ago

Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint

May 30, 2025, 6:00 AM EDT - 4 months ago

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

May 2, 2025, 1:06 AM EDT - 5 months ago

Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript

May 1, 2025, 6:20 PM EDT - 5 months ago

Final Trade: NVS, XLU and SMMT

NVS XLU

May 1, 2025, 4:09 PM EDT - 5 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

Apr 28, 2025, 1:00 PM EDT - 5 months ago

Why Is Summit Therapeutics Stock Trading Higher On Monday?

Apr 25, 2025, 3:14 PM EDT - 5 months ago

What's Going On With Summit Therapeutics Stock On Friday?

Apr 25, 2025, 2:50 PM EDT - 5 months ago

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Apr 24, 2025, 4:15 PM EDT - 5 months ago

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Apr 23, 2025, 3:47 PM EDT - 5 months ago

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Apr 23, 2025, 6:15 AM EDT - 5 months ago

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Apr 14, 2025, 9:08 AM EDT - 5 months ago

Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition

Mar 24, 2025, 2:17 PM EDT - 6 months ago

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics

Mar 17, 2025, 4:24 PM EDT - 6 months ago

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

Feb 24, 2025, 8:13 PM EST - 7 months ago

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

PFE

Feb 24, 2025, 3:33 PM EST - 7 months ago

Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program

Feb 24, 2025, 12:15 PM EST - 7 months ago

Summit Therapeutics Inc. (SMMT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 10:53 AM EST - 7 months ago

Pfizer: What The Summit Therapeutics Deal Brings

PFE

Feb 24, 2025, 6:05 AM EST - 7 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Feb 24, 2025, 6:00 AM EST - 7 months ago

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

PFE

Feb 18, 2025, 9:00 AM EST - 7 months ago

Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Jan 18, 2025, 9:33 AM EST - 8 months ago

Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)

Jan 13, 2025, 6:10 PM EST - 8 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 7, 2025, 7:00 AM EST - 9 months ago

Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

TruthBroker2 Sep. 20 at 10:30 PM

$SMMT

0 · Reply

Doozio Sep. 20 at 2:40 PM

$SUPN thing about MNDY 🐑 lows and tight weekly closes. $SYM thing about Roger coming out of the tightness and $SMMT thing about potential tightness bahhhhtom of the base 🐒🍌🧠⏰♾️

1 · Reply

goooooolddust Sep. 20 at 4:31 AM

$SMMT they just keep buying lol

0 · Reply

Newyork_ Sep. 20 at 12:37 AM

$SMMT oh Thankgod Cramer is bearish on us . 😂😂😂 ima load more .

1 · Reply

Knowhentoprofit Sep. 19 at 9:15 PM

$SMMT hahaha

2 · Reply

TruthBroker2 Sep. 19 at 8:04 PM

$SMMT

0 · Reply

Magic8BallResponse Sep. 19 at 7:15 PM

$SMMT Feeling that tingle.....

0 · Reply

BigFishLittleBish Sep. 19 at 6:06 PM

3 · Reply

TruthBroker2 Sep. 19 at 5:45 PM

$SMMT

0 · Reply

BigBeardTrader Sep. 19 at 5:11 PM

$SMMT https://www.marketbeat.com/instant-alerts/filing-rockland-trust-co-buys-shares-of-400000-summit-therapeutics-plc-smmt-2025-09-19/

0 · Reply

EB2224 Sep. 19 at 4:51 PM

$SMMT 🐂

0 · Reply

Boom1166 Sep. 19 at 4:46 PM

$SMMT

0 · Reply

Pastor100 Sep. 19 at 4:44 PM

$SMMT I have been asked to come back to keep making retail lose money here on a super over valued stock that has a drug no better than keytruda hyped up China crooks!

1 · Reply

EB2224 Sep. 19 at 4:41 PM

$SMMT for anyone new to this board, Pastor100 coming back is EXCELLENT news for this stock.

1 · Reply

Pastor100 Sep. 19 at 4:36 PM

$SMMT The recent $235 million equity raise (September 2025 at $22.70/share) added cash but diluted shareholders by ~10 million shares, eroding per-share value

1 · Reply

Pastor100 Sep. 19 at 4:07 PM

$SMMT You people realize you are paying a 17$ premium for this stock it has intrinsic value of $2.17

1 · Reply

BagHolderBros Sep. 19 at 4:03 PM

$SMMT

0 · Reply

cubie Sep. 19 at 3:47 PM

$FDS u were saying omega? 🙄😒cubie teaches u cant knife catch everything u see on day 1. u havent learned that lesson from $LULU $SMMT and several more where u became a baggie on🙈🙄

1 · Reply

TruthBroker2 Sep. 19 at 3:28 PM

$SMMT

0 · Reply

BigBeardTrader Sep. 19 at 3:24 PM

$SMMT Expanding Pipeline is great news. https://www.healio.com/news/hematology-oncology/20250918/fda-grants-orphan-drug-designation-to-ligufalimab-for-acute-myeloid-leukemia

0 · Reply

SmokeWagon Sep. 19 at 2:15 PM

$SMMT

0 · Reply

RadioIsotope25 Sep. 19 at 1:38 PM

$RADX Lantheus owns the imaging agent for Radiopharm Theranostics HER2 Lu-177 therapeutic drug. Similar drug to Rad’s: https://pubmed.ncbi.nlm.nih.gov/27813061/#:~:text=The%20patient%20studies%20showed%20the,disseminated%20HER2%20positive%20breast%20cancer. $LNTH $SMMT $IMNM

0 · Reply

Market Cap	14.03B
Revenue (ttm)	0.00
Net Income (ttm)	-221.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	9,197,600
Avg Vol	3,919,640
Day's Range	N/A - N/A
Shares Out	742.85M
Stochastic %K	70%
Beta	-1.02
Analysts	Strong Sell
Price Target	$32.69